相似文献
1
Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3(Suppl 3):S249-65.
2
Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S121-2. doi: 10.1086/591391.
3
Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S237-40. doi: 10.1086/591408.
4
Proceedings of the Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia, January 2008.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S105-265. doi: 10.1086/596018.
5
Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia.
Clin Infect Dis. 2008 Apr 15;46(8):1152-6. doi: 10.1086/533442.
6
Comments on: Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin and comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Curr Med Res Opin. 2004 Dec;20(12):1895-6; author reply 1896-7. doi: 10.1185/030079904X11600.
7
Macrolides in community-acquired pneumonia: does the bell toll for thee?
Chest. 2005 Sep;128(3):1089-93. doi: 10.1378/chest.128.3.1089.
8
Severe community-acquired pneumonia.
Neth J Med. 1999 Sep;55(3):103-5. doi: 10.1016/s0300-2977(99)00072-8.
9
A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Clin Infect Dis. 2012 Oct;55(8):1122-3. doi: 10.1093/cid/cis567. Epub 2012 Jun 28.
10
Community-Acquired Pneumonia: Determining Safe Treatment in the Outpatient Setting.
Am Fam Physician. 2019 Jun 15;99(12):768-769.
引用本文的文献
1
Comprehensive analysis of antibiotic resistance in Enterobacteriaceae from outpatient urine cultures: Implications for empirical therapy.
North Clin Istanb. 2025 Jan 31;12(1):36-44. doi: 10.14744/nci.2024.25564. eCollection 2025.
2
Antibiotic duration for common bacterial infections-a systematic review.
JAC Antimicrob Resist. 2025 Jan 29;7(1):dlae215. doi: 10.1093/jacamr/dlae215. eCollection 2025 Feb.
3
Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
Clin Infect Dis. 2024 Jul 19;79(1):60-69. doi: 10.1093/cid/ciae163.
4
Pragmatic Adaptive Trial for Respiratory Infection in Children (PATRIC) Clinical Registry protocol.
BMJ Open. 2024 Jan 25;14(1):e074308. doi: 10.1136/bmjopen-2023-074308.
5
Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis.
BMJ Open. 2023 Mar 22;13(3):e061023. doi: 10.1136/bmjopen-2022-061023.
6
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.
JAMA. 2021 Nov 2;326(17):1713-1724. doi: 10.1001/jama.2021.17843.
7
Community-acquired pneumonia: similarities and differences between European and American guidelines - A narrative review.
Rev Esp Quimioter. 2021 Apr;34(2):72-80. doi: 10.37201/req/114.2020. Epub 2020 Dec 9.
8
Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.
Front Public Health. 2020 Nov 4;8:535668. doi: 10.3389/fpubh.2020.535668. eCollection 2020.
9
The Concept of an Ideal Antibiotic: Implications for Drug Design.
Molecules. 2019 Mar 3;24(5):892. doi: 10.3390/molecules24050892.
10
Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.
Cochrane Database Syst Rev. 2016 Nov 14;11(11):CD005598. doi: 10.1002/14651858.CD005598.pub4.
本文引用的文献
1
THE TREATMENT OF PNEUMOCOCCAL PNEUMONIA WITH DAGENAN (M. & B. 693).
Can Med Assoc J. 1939 Apr;40(4):325-32.
2
Results of the Treatment of 400 Cases of Lobar Pneumonia with M & B 693: (Section of Medicine).
Proc R Soc Med. 1939 Jul;32(9):1070-6. doi: 10.1177/003591573903200923.
3
Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S241-8. doi: 10.1086/591410.
4
Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S225-31. doi: 10.1086/591427.
5
Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S216-24. doi: 10.1086/591407.
6
Is it possible to blind a trial for community-acquired pneumonia?
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S210-5. doi: 10.1086/591428.
7
Novel approaches to the identification of Streptococcus pneumoniae as the cause of community-acquired pneumonia.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S202-6. doi: 10.1086/591405.
8
Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S180-5. doi: 10.1086/591401.
9
Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3(Suppl 3):S176-9. doi: 10.1086/591400.
10
Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S166-75. doi: 10.1086/591399.
Zotero 插件